Skip to main content
Signal8
Launch Terminal

Scribe Therapeutics, Inc. (SCTX)

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Scribe Therapeutics Inc. logo

Scribe Therapeutics Inc.

NASDAQ:SCTXHealthcare
-14.23%$15.40
AH Close$15.40+0.00%vs close
Mkt Cap$291.64M
Float12.04M
O/S18.93M
Inst Own0.0%
SI20.5%
Dilution
Scribe Therapeutics Inc. logoNASDAQ:SCTX$15.40-14.23%
FormDescription
10-Q
Quarterly Report
8-K
2.02,9.01
13G
Beneficial Ownership Report
13D
Beneficial Ownership Report (Active)
13D
Beneficial Ownership Report (Active)
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
13D
Beneficial Ownership Report (Active)
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
8-K
5.03,9.01
S-8
SEC Filing
424B4
Prospectus
EFFECT
Notice of Effectiveness
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership

1-25 of 46